Emerging treatments such as EBV-targeted immunotherapies, immune checkpoint inhibitors, and targeted therapies against MYC and NF-κB pathways are under investigation for better management of HIV-associated lymphomas. This evidence concerns the gene NFKB1 and lymphoma.